{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T12:37:08Z","timestamp":1792931828728,"version":"4.5.0"},"reference-count":176,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008384","name":"Stifterverband","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008384","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Epigenetic regulation of gene expression entails DNA methylation and histone modifications, which orchestrate chromatin structure and transcriptional activity. Aberrant regulation of these mechanisms contributes to the development and progression of hematological cancers. Mutations in enzymes mediating DNA methylation and histone modification patterns reshape chromatin structure, influencing transcriptional profiles, thus promoting oncogenesis, clonal evolution and drug resistance. This review focuses on significant alterations in DNA methylation patterns, mutations and changes in expression of histone modifying enzymes and chromatin remodeling complexes described in leukemias, lymphomas and multiple myeloma. We summarize the most prominent changes in epigenetic mediators and their impact on transcriptional activity and oncogenesis.<\/jats:p>","DOI":"10.3389\/fonc.2026.1744018","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T05:23:13Z","timestamp":1770268993000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["The role of epigenetic modifications in hematological cancers"],"prefix":"10.3389","volume":"16","author":[{"given":"Jovana","family":"Ilic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Bold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Knop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"20150445","DOI":"10.1098\/rstb.2015.0445","article-title":"Epigenetic inheritance systems contribute to the evolution of a germline","volume":"371","author":"Lachmann","year":"2016","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/ng1089","article-title":"Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals","volume":"33","author":"Jaenisch","year":"2003","journal-title":"Nat Gen"},{"key":"B3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nrg3863","article-title":"RNA-mediated epigenetic regulation of gene expression","volume":"16","author":"Holoch","year":"2015","journal-title":"Nat Rev Genet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3907","article-title":"Haematological Malignancies: at the forefront of immunotherapeutic innovation","volume":"15","author":"Bachireddy","year":"2015","journal-title":"Nat Rev Cancer."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.01.025","article-title":"Hematopoiesis: an evolving paradigm for stem cell biology","volume":"132","author":"Orkin","year":"2008","journal-title":"Cell."},{"key":"B6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41392-023-01342-6","article-title":"Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic Malignancies","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4419-9967-2_1","article-title":"DNA methyltransferases, DNA damage repair, and cancer","volume":"754","author":"Jin","year":"2013","journal-title":"Adv Exp Med Biol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1038\/s41467-020-17109-4","article-title":"Comprehensive structure-function characterization of DNMT3B and DNMT3A reveals distinctive de novo DNA methylation mechanisms","volume":"11","author":"Gao","year":"2020","journal-title":"Nat Commun"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2015.06.015","article-title":"DNMT3A intragenic hypomethylation is associated with adverse prognosis in acute myeloid leukemia","volume":"39","author":"Zhang","year":"2015","journal-title":"Leuk Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4218","article-title":"Genetic unmasking of an epigenetically silenced microRNA in human cancer cells","volume":"67","author":"Lujambio","year":"2007","journal-title":"Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1177271919846454","DOI":"10.1177\/1177271919846454","article-title":"Oncogenic roles and inhibitors of DNMT1, DNMT3A, and DNMT3B in acute myeloid leukaemia","volume":"14","author":"Wong","year":"2019","journal-title":"biomark Insights"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3788","DOI":"10.1016\/j.ebiom.2020.103191","article-title":"Dnmt3b catalytic activity is critical for its tumour suppressor function in lymphomagenesis and is associated with c-Met oncogenic signalling","volume":"63","author":"Lopusna","year":"2021","journal-title":"EBioMedicine."},{"key":"B13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/imr.2014.263.issue-1","article-title":"TET proteins and 5-methylcytosine oxidation in hematological cancers","volume":"263","author":"Ko","year":"2015","journal-title":"Immunol Rev"},{"key":"B14","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41392-023-01537-x","article-title":"TET (Ten-eleven translocation) family proteins: structure, biological functions and applications","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/cas.v112.1","article-title":"TET2: A cornerstone in normal and Malignant hematopoiesis","volume":"112","author":"Kunimoto","year":"2021","journal-title":"Cancer Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1005143","article-title":"DNMT3A mutations in acute myeloid leukemia","volume":"363","author":"Ley","year":"2010","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.77","article-title":"DNMT3A mutations in myeloproliferative neoplasms","volume":"25","author":"Stegelmann","year":"2011","journal-title":"Leukemia."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-311019","article-title":"Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A","volume":"118","author":"Jankowska","year":"2011","journal-title":"Blood."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1111708","article-title":"TET2 and DNMT3A mutations in human T-cell lymphoma","volume":"366","author":"Couronn\u00e9","year":"2012","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.22039","article-title":"The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL","volume":"52","author":"Grossmann","year":"2013","journal-title":"Genes Chromosomes Cancer."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3895","article-title":"DNMT3A in haematological Malignancies","volume":"15","author":"Yang","year":"2015","journal-title":"Nat Rev Cancer."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-594648","article-title":"Dnmt3a loss predisposes murine hematopoietic stem cells to Malignant transformation","volume":"125","author":"Mayle","year":"2015","journal-title":"Blood."},{"key":"B23","doi-asserted-by":"publisher","first-page":"5416923","DOI":"10.1155\/2018\/5416923","article-title":"Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment","volume":"2018","author":"Phi","year":"2018","journal-title":"Stem Cells Int"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nature13038","article-title":"Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia","volume":"506","author":"Shlush","year":"2014","journal-title":"Nature."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-840132","article-title":"Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma","volume":"132","author":"Walker","year":"2018","journal-title":"Blood."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202493","article-title":"Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis","volume":"190","author":"Heuck","year":"2013","journal-title":"J Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40364-017-0081-z","article-title":"DNA methyltransferases and their roles in tumorigenesis","volume":"5","author":"Zhang","year":"2017","journal-title":"biomark Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0235","article-title":"Inactivation of receptor tyrosine kinases reverts aberrant DNA methylation in acute myeloid leukemia","volume":"23","author":"Shen","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2014.2481","article-title":"Knockdown of DNA methyltransferase-1 inhibits proliferation and derepresses tumor suppressor genes in myeloma cells","volume":"8","author":"Zhou","year":"2014","journal-title":"Oncol Lett"},{"key":"B30","article-title":"Patterns of DNMT1 promoter methylation in patients with acute lymphoblastic leukemia","volume":"11","author":"Rahmani","year":"2017","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2017.6050","article-title":"Nota ble roles of EZH2 and DNMT1 in epigenetic dormancy of the SHP1 gene during the progression of chronic myeloid leukaemia","volume":"13","author":"Wang","year":"2017","journal-title":"Oncol Lett"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2014.11.025","article-title":"\u03b2-Arrestin1 promotes the self-renewal of the leukemia-initiating cell-enriched subpopulation in B-lineage acute lymphoblastic leukemia related to DNMT1 activity","volume":"357","author":"Shu","year":"2015","journal-title":"Cancer Lett"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2017.293","article-title":"MN1 overexpression is driven by loss of DNMT3B methylation activity in inv(16) pediatric AML","volume":"37","author":"Larmonie","year":"2018","journal-title":"Oncogene."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.20176","article-title":"DNMT3B overexpression contributes to aberrant DNA methylation and MYC-driven tumor maintenance in T-ALL and Burkitt\u2019s lymphoma","volume":"8","author":"Poole","year":"2017","journal-title":"Oncotarget."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-0847","article-title":"DNMT3B7, a truncated DNMT3B isoform expressed in human tumors, disrupts embryonic development and accelerates lymphomagenesis","volume":"70","author":"Shah","year":"2010","journal-title":"Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019791475","article-title":"Dysregulation of the TET family of epigenetic regulators in lymphoid and myeloid Malignancies","volume":"134","author":"Lio","year":"2019","journal-title":"Blood."},{"key":"B37","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41408-018-0057-8","article-title":"Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic\/myeloproliferative neoplasms","volume":"8","author":"Lasho","year":"2018","journal-title":"Blood Cancer J"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.59","article-title":"Detection of mutant TET2 in myeloid Malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS\/MPN and AML","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3148","article-title":"TET1 is a tumor suppressor of hematopoietic Malignancy","volume":"16","author":"Cimmino","year":"2015","journal-title":"Nat Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s13148-024-01771-2","article-title":"TET2 mutation in acute myeloid leukemia: biology, clinical significance, and therapeutic insights","volume":"16","author":"Gao","year":"2024","journal-title":"Clin Epigenetics."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3390\/ijms21020626","article-title":"Age-associated TET2 mutations: common drivers of myeloid dysfunction, cancer and cardiovascular disease","volume":"21","author":"Ferrone","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-210039","article-title":"Genetic characterization of TET1, TET2, and TET3 alterations in myeloid Malignancies","volume":"114","author":"Abdel-Wahab","year":"2009","journal-title":"Blood."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1112317108","article-title":"Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice","volume":"108","author":"Ko","year":"2011","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B45","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2011.06.001","article-title":"Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation","volume":"20","author":"Moran-Crusio","year":"2011","journal-title":"Cancer Cell"},{"key":"B46","doi-asserted-by":"publisher","first-page":"15102","DOI":"10.1038\/ncomms15102","article-title":"Tet2 loss leads to hypermutagenicity in haematopoietic stem\/progenitor cells","volume":"8","author":"Pan","year":"2017","journal-title":"Nat Commun"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024015149","article-title":"Persistent postremission clonal hematopoiesis shapes the relapse trajectories of acute myeloid leukemia","volume":"9","author":"Chow","year":"2025","journal-title":"Blood Adv"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/nature09586","article-title":"Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2","volume":"468","author":"Ko","year":"2010","journal-title":"Nature."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-324707","article-title":"Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors","volume":"118","author":"Pronier","year":"2011","journal-title":"Blood."},{"key":"B50","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ccr.2011.06.003","article-title":"TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis","volume":"20","author":"Quivoron","year":"2011","journal-title":"Cancer Cell"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-552471","article-title":"Tet2-mutated myeloid progenitors possess aberrant in vitro self-renewal capacity","volume":"123","author":"Kunimoto","year":"2014","journal-title":"Blood."},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2015.07.025","article-title":"Overlapping requirements for tet2 and tet3 in normal development and hematopoietic stem cell emergence","volume":"12","author":"Li","year":"2015","journal-title":"Cell Rep"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1903059116","article-title":"Paradoxical association of TET loss of function with genome-wide DNA hypomethylation","volume":"116","author":"L\u00f3pez-Moyado","year":"2019","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/embor.2011.43","article-title":"The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases","volume":"12","author":"Chowdhury","year":"2011","journal-title":"EMBO Rep"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.275","article-title":"Isocitrate dehydrogenase mutations in myeloid Malignancies","volume":"31","author":"Medeiros","year":"2017","journal-title":"Leukemia."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2014.11.004","article-title":"DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia","volume":"9","author":"Rampal","year":"2014","journal-title":"Cell Rep"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-644591","article-title":"IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma","volume":"126","author":"Wang","year":"2015","journal-title":"Blood."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-391748","article-title":"IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma","volume":"119","author":"Cairns","year":"2012","journal-title":"Blood."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1617929114","article-title":"The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development","volume":"113","author":"Lemonnier","year":"2016","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/path.v250.3","article-title":"Angioimmunoblastic T-cell lymphoma contains multiple clonal T-cell populations derived from a common TET2 mutant progenitor cell","volume":"250","author":"Yao","year":"2020","journal-title":"J Pathol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-200519","article-title":"MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation","volume":"114","author":"Figueroa","year":"2009","journal-title":"Blood."},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-06-163246","article-title":"Aberrant DNA methylation is a dominant mechanism in MDS progression to AML","volume":"113","author":"Jiang","year":"2009","journal-title":"Blood."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1101\/gr.269233.120","article-title":"DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia","volume":"31","author":"Giacopelli","year":"2021","journal-title":"Genome Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.12","article-title":"A CpG island methylator phenotype in acute myeloid leukemia independent of IDH mutations and associated with a favorable outcome","volume":"31","author":"Kelly","year":"2017","journal-title":"Leukemia."},{"key":"B66","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13148-024-01625-x","article-title":"MethScore as a new comprehensive DNA methylation-based value refining the prognosis in acute myeloid leukemia","volume":"16","author":"\u0160est\u00e1kov\u00e1","year":"2024","journal-title":"Clin Epigenetics."},{"key":"B67","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41698-022-00295-3","article-title":"Peripheral blood DNA methylation profiles predict future development of B-cell Non-Hodgkin Lymphoma","volume":"6","author":"Esp\u00edn-P\u00e9rez","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.979569","article-title":"Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity","volume":"12","author":"Muylaert","year":"2022","journal-title":"Front Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1101\/gr.180240.114","article-title":"Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers","volume":"25","author":"Agirre","year":"2015","journal-title":"Genome Res"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.7.2500","article-title":"Frequent hypermethylation of p16 and p15 genes in multiple myeloma","volume":"89","author":"Ng","year":"1997","journal-title":"Blood."},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404939","article-title":"Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma","volume":"21","author":"Chim","year":"2007","journal-title":"Leukemia."},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0404-1","article-title":"Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options","volume":"33","author":"van Andel","year":"2019","journal-title":"Leukemia."},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-009084","article-title":"ABCG2 expression, function, and promoter methylation in human multiple myeloma","volume":"108","author":"Turner","year":"2006","journal-title":"Blood."},{"key":"B74","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1053\/j.seminhematol.2008.09.008","article-title":"Epigenetics of acute lymphocytic leukemia","volume":"46","author":"Garcia-Manero","year":"2009","journal-title":"Semin Hematol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.2217\/epi-2016-0052","article-title":"DNA methylome analysis of acute lymphoblastic leukemia cells reveals stochastic de novo DNA methylation in CpG islands","volume":"8","author":"Wahlberg","year":"2016","journal-title":"Epigenomics."},{"key":"B76","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41597-020-0456-0","article-title":"DNA methylation of chronic lymphocytic leukemia with differential response to chemotherapy","volume":"7","author":"Yosifov","year":"2020","journal-title":"Sci Data."},{"key":"B77","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1515\/oncologie-2024-0324","article-title":"Histone methylation and acetylation in cancer: mechanism, progression, and targets","volume":"27","author":"Bu","year":"2025","journal-title":"Oncologie."},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2012.00026","article-title":"Histone ubiquitination and deubiquitination in transcription, DNA damage response, and cancer","volume":"2","author":"Cao","year":"2012","journal-title":"Front Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/47412","article-title":"The language of covalent histone modifications","volume":"403","author":"Strahl","year":"2000","journal-title":"Nature."},{"key":"B80","doi-asserted-by":"publisher","first-page":"e324","DOI":"10.1038\/emm.2017.11","article-title":"Writing, erasing and reading histone lysine methylations","volume":"49","author":"Hyun","year":"2017","journal-title":"Exp Mol Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601639","article-title":"ALL-1\/MLL1, a homologue of Drosophila TRITHORAX, modifies chromatin and is directly involved in infant acute leukaemia","volume":"90","author":"Canaani","year":"2004","journal-title":"Br J Cancer."},{"key":"B82","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.exphem.2014.09.006","article-title":"Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia","volume":"42","author":"Li","year":"2014","journal-title":"Exp Hematol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1080\/15384101.2019.1618642","article-title":"Hematopoietic transformation in the absence of MLL1\/KMT2A: distinctions in target gene reactivation","volume":"18","author":"Chen","year":"2019","journal-title":"Cell Cycle"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(02)00740-2","article-title":"ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation","volume":"10","author":"Nakamura","year":"2002","journal-title":"Mol Cell"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2015.174","article-title":"Role of HOXA9 in leukemia: dysregulation, cofactors and essential targets","volume":"35","author":"Collins","year":"2016","journal-title":"Oncogene."},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/frhem.2025.1668408","article-title":"H3K27me3 and HOXA9 expression predict prognosis in pediatric acute myeloid leukemia: an epigenetic-transcriptional correlation study","volume":"4","author":"Goto","year":"2025","journal-title":"Front Hematol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.ccell.2018.08.018","article-title":"HOXA9 reprograms the enhancer landscape to promote leukemogenesis","volume":"34","author":"Sun","year":"2018","journal-title":"Cancer Cell"},{"key":"B88","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s40364-025-00786-y","article-title":"Insights into KMT2A rearrangements in acute myeloid leukemia: from molecular characteristics to targeted therapies","volume":"13","author":"Zehtabcheh","year":"2025","journal-title":"biomark Res"},{"key":"B89","doi-asserted-by":"publisher","first-page":"e18656","DOI":"10.7717\/peerj.18656","article-title":"The epigenetic role of EZH2 in acute myeloid leukemia","volume":"12","author":"Fang","year":"2024","journal-title":"PeerJ."},{"key":"B90","doi-asserted-by":"publisher","first-page":"e549","DOI":"10.1038\/bcj.2017.27","article-title":"Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control","volume":"7","author":"Pawlyn","year":"2017","journal-title":"Blood Cancer J"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-394932","article-title":"Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia","volume":"120","author":"Tanaka","year":"2012","journal-title":"Blood."},{"key":"B92","doi-asserted-by":"publisher","first-page":"5838","DOI":"10.1038\/s41598-021-84708-6","article-title":"Loss-of-function mutations in the histone methyltransferase EZH2 promote chemotherapy resistance in AML","volume":"11","author":"Kempf","year":"2021","journal-title":"Sci Rep"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1439","article-title":"Chronic myelogenous leukemia- initiating cells require polycomb group protein EZH2","volume":"6","author":"Xie","year":"2016","journal-title":"Cancer Discov"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01925-w","article-title":"Aberrant activation of TRIP13-EZH2 signaling axis promotes stemness and therapy resistance in multiple myeloma","volume":"37","author":"Xu","year":"2023","journal-title":"Leukemia."},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.12.3896","article-title":"Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of Malignancy in B-cell non-Hodgkin lymphoma","volume":"97","author":"van Kemenade","year":"2001","journal-title":"Blood."},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-450494","article-title":"EZH2 overexpression in natural killer\/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity","volume":"121","author":"Yan","year":"2013","journal-title":"Blood."},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.32","article-title":"EZH2 alterations in follicular lymphoma: biological and clinical correlations","volume":"7","author":"Huet","year":"2017","journal-title":"Blood Cancer J"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat Genet"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/ng.621","article-title":"Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders","volume":"42","author":"Ernst","year":"2010","journal-title":"Nat Genet"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0486","article-title":"EZH2 inhibition blocks multiple myeloma cell growth through upregulation of epithelial tumor suppressor genes","volume":"15","author":"Hernando","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01983-0","article-title":"EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma","volume":"37","author":"Chemlal","year":"2023","journal-title":"Leukemia."},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2022.13.2.7","article-title":"Tazemetostat: EZH2 inhibitor","volume":"13","author":"Straining","year":"2022","journal-title":"J Adv Pract Oncol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"e25299","DOI":"10.7554\/eLife.25299","article-title":"RNA-dependent stabilization of SUV39H1 at constitutive heterochromatin","volume":"6","author":"Johnson","year":"2017","journal-title":"Elife."},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-01495-6","article-title":"SUV39H1 regulates the progression of MLL-AF9-induced acute myeloid leukemia","volume":"39","author":"Chu","year":"2020","journal-title":"Oncogene."},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00705","article-title":"The emerging role of H3K9me3 as a potential therapeutic target in acute myeloid leukemia","volume":"9","author":"Monaghan","year":"2019","journal-title":"Front Oncol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-240978","article-title":"Profiling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia","volume":"116","author":"M\u00fcller-Tidow","year":"2010","journal-title":"Blood."},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.361","article-title":"Reexpression of epigenetically silenced AML tumor suppressor genes by SUV39H1 inhibition","volume":"29","author":"Lakshmikuttyamma","year":"2010","journal-title":"Oncogene."},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-298349","article-title":"The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t (4,14) multiple myeloma cells","volume":"117","author":"Martinez-Garcia","year":"2011","journal-title":"Blood."},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1675","article-title":"In multiple myeloma, t (4,14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression","volume":"101","author":"Keats","year":"2003","journal-title":"Blood."},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.116","article-title":"MMSET\/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents","volume":"35","author":"Shah","year":"2016","journal-title":"Oncogene."},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-05-088674","article-title":"The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity","volume":"111","author":"Lauring","year":"2008","journal-title":"Blood."},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1004566","article-title":"Histone methyltransferase MMSET\/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation","volume":"10","author":"Popovic","year":"2014","journal-title":"PloS Genet"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00255","article-title":"Lysine-specific demethylase 1A as a promising target in acute myeloid leukemia","volume":"8","author":"Magliulo","year":"2018","journal-title":"Front Oncol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.18564","article-title":"Upregulation of CD11b and CD86 through LSD1 inhibition promotes myeloid differentiation and suppresses cell proliferation in human monocytic leukemia cells","volume":"8","author":"Fang","year":"2017","journal-title":"Oncotarget."},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.03.014","article-title":"The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells","volume":"21","author":"Harris","year":"2012","journal-title":"Cancer Cell"},{"key":"B116","doi-asserted-by":"publisher","first-page":"e0135981","DOI":"10.1371\/journal.pone.0135981","article-title":"Prognostic value of CD11b expression level for acute myeloid leukemia patients: A meta-analysis","volume":"10","author":"Xu","year":"2015","journal-title":"PloS One"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20526","article-title":"Expression of MAC-1 (CD11b) in acute myeloid leukemia (AML) is associated with an unfavorable prognosis","volume":"81","author":"Graf","year":"2006","journal-title":"Am J Hematol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"9988405","DOI":"10.1155\/2023\/9988405","article-title":"CD86 is associated with immune infiltration and immunotherapy signatures in AML and promotes its progression","volume":"2023","author":"Zhang","year":"2023","journal-title":"J Oncol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-569525","article-title":"Lysine-specific demethylase 1 (LSD1) in hematopoietic and lymphoid neoplasms","volume":"124","author":"Niebel","year":"2014","journal-title":"Blood."},{"key":"B120","doi-asserted-by":"publisher","first-page":"117830","DOI":"10.1016\/j.biopha.2025.117830","article-title":"Dual effect of targeting LSD1 on the invasiveness and the mechanical response of acute lymphoblastic leukemia cells","volume":"183","author":"Gonz\u00e1lez-Novo","year":"2025","journal-title":"BioMed Pharmacother."},{"key":"B121","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12943-019-1127-7","article-title":"Role of HDACs in normal and Malignant hematopoiesis","volume":"19","author":"Wang","year":"2020","journal-title":"Mol Cancer."},{"key":"B122","doi-asserted-by":"publisher","first-page":"101957","DOI":"10.1016\/j.smim.2025.101957","article-title":"Acetylation and deacetylation dynamics in stress response to cancer and infections","volume":"78","author":"Li","year":"2025","journal-title":"Semin Immunol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1038\/nature09727","article-title":"CREBBP mutations in relapsed acute lymphoblastic leukaemia","volume":"471","author":"Mullighan","year":"2011","journal-title":"Nature."},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1038\/nature09730","article-title":"Inactivating mutations of acetyltransferase genes in B-cell lymphoma","volume":"471","author":"Pasqualucci","year":"2011","journal-title":"Nature."},{"key":"B125","doi-asserted-by":"publisher","first-page":"e55481","DOI":"10.1371\/journal.pone.0055481","article-title":"A histone acetyltransferase p300 inhibitor C646 induces cell cycle arrest and apoptosis selectively in AML1-ETO-positive AML cells","volume":"8","author":"Gao","year":"2013","journal-title":"PloS One"},{"key":"B126","doi-asserted-by":"publisher","first-page":"e1491","DOI":"10.1038\/cddis.2014.433","article-title":"HDAC1 and Klf4 interplay critically regulates human myeloid leukemia cell proliferation","volume":"5","author":"Huang","year":"2014","journal-title":"Cell Death Dis"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1038\/35901","article-title":"Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia","volume":"391","author":"Grignani","year":"1998","journal-title":"Nature."},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.18.12.7185","article-title":"Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO","volume":"18","author":"Gelmetti","year":"1998","journal-title":"Mol Cell Biol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007998","article-title":"HDAC1 regulates the chromatin landscape to control transcriptional dependencies in chronic lymphocytic leukemia","volume":"7","author":"Lai","year":"2023","journal-title":"Blood Adv"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2018.07.017","article-title":"HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR\/ABL1","volume":"370","author":"Bamodu","year":"2018","journal-title":"Exp Cell Res"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.576391","article-title":"Recent update of HDAC inhibitors in lymphoma","volume":"8","author":"Chen","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.4161\/15592294.2014.983367","article-title":"Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma","volume":"9","author":"Mithraprabhu","year":"2014","journal-title":"Epigenetics."},{"key":"B133","doi-asserted-by":"publisher","first-page":"107057","DOI":"10.1016\/j.ejps.2025.107057","article-title":"Clinical efficacy and mechanistic insights of FDA-approved HDAC inhibitors in the treatment of lymphoma","volume":"208","author":"El Omari","year":"2025","journal-title":"Eur J Pharm Sci"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1038\/nrm.2017.26","article-title":"Mechanisms of action and regulation of ATP-dependent chromatin-remodelling complexes","volume":"18","author":"Clapier","year":"2017","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12943-023-01736-8","article-title":"SWI\/SNF complexes in hematological Malignancies: biological implications and therapeutic opportunities","volume":"22","author":"Andrades","year":"2023","journal-title":"Mol Cancer."},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006235","article-title":"SMARCD1 negatively regulates myeloid differentiation of leukemic cells via epigenetic mechanisms","volume":"6","author":"Saha","year":"2022","journal-title":"Blood Adv"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.69","article-title":"Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia","volume":"30","author":"Madan","year":"2016","journal-title":"Leukemia."},{"key":"B138","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ccell.2024.02.010","article-title":"ARID1A orchestrates SWI\/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis","volume":"42","author":"Barisic","year":"2024","journal-title":"Cancer Cell"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1080\/15592294.2017.1282587","article-title":"Follicular lymphoma, a B cell Malignancy addicted to epigenetic mutations","volume":"12","author":"Korfi","year":"2017","journal-title":"Epigenetics."},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026588","article-title":"Loss of BCL7A permits IRF4 transcriptional activity and cellular growth in multiple myeloma","volume":"146","author":"Chakraborty","year":"2025","journal-title":"Blood."},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-318873","article-title":"The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemia","volume":"118","author":"Gutierrez","year":"2011","journal-title":"Blood."},{"key":"B142","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s42003-024-05917-z","article-title":"Differential requirements for Smarca5 expression during hematopoietic stem cell commitment","volume":"7","author":"Turkova","year":"2024","journal-title":"Commun Biol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2004.05.013","article-title":"Removal of promoter nucleosomes by disassembly rather than sliding in vivo","volume":"14","author":"Boeger","year":"2004","journal-title":"Mol Cell"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.4161\/15384101.2014.956551","article-title":"ISWI chromatin remodeling complexes in the DNA damage response","volume":"13","author":"Aydin","year":"2014","journal-title":"Cell Cycle"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.01070-14","article-title":"Nucleosome spacing generated by ISWI and CHD1 remodelers is constant regardless of nucleosome density","volume":"35","author":"Lieleg","year":"2015","journal-title":"Mol Cell Biol"},{"key":"B146","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s13046-021-02151-x","article-title":"The emerging role of ISWI chromatin remodeling complexes in cancer","volume":"40","author":"Li","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401807","article-title":"Chromatin remodeling gene SMARCA5 is dysregulated in primitive hematopoietic cells of acute leukemia","volume":"14","author":"Stopka","year":"2000","journal-title":"Leukemia."},{"key":"B148","doi-asserted-by":"publisher","first-page":"e87448","DOI":"10.1371\/journal.pone.0087448","article-title":"Epigenetic control of SPI1 gene by CTCF and ISWI ATPase SMARCA5","volume":"9","author":"Dluhosova","year":"2014","journal-title":"PloS One"},{"key":"B149","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.3390\/ijms21062073","article-title":"Loss of ISWI ATPase SMARCA5 (SNF2H) in acute myeloid leukemia cells inhibits proliferation and chromatid cohesion","volume":"21","author":"Zikmund","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B150","doi-asserted-by":"publisher","first-page":"e7169","DOI":"10.1371\/journal.pone.0007169","article-title":"Investigating the targets of MIR-15a and MIR-16\u20131 in patients with chronic lymphocytic leukemia (CLL)","volume":"4","author":"Hanlon","year":"2009","journal-title":"PloS One"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1101\/gad.348897.121","article-title":"Sentinels of chromatin: chromodomain helicase DNA-binding proteins in development and disease","volume":"35","author":"Alendar","year":"2021","journal-title":". Genes Dev"},{"key":"B152","doi-asserted-by":"publisher","first-page":"18923","DOI":"10.1038\/s41598-024-68644-9","article-title":"Molecular characteristics and oncogenic role of CHD family genes: a pan-cancer analysis based on bioinformatic and biological analysis","volume":"14","author":"Lu","year":"2024","journal-title":"Sci Rep"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-631606","article-title":"Depletion of the chromatin remodeler CHD4 sensitizes AML blasts to genotoxic agents and reduces tumor formation","volume":"126","author":"Sperlazza","year":"2015","journal-title":"Blood."},{"key":"B154","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1182\/blood-2014-10-604959","article-title":"Mutations in CHD2 cause defective association with active chromatin in chronic lymphocytic leukemia","volume":"126","author":"Rodr\u00edguez","year":"2015","journal-title":"Blood."},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-20-2276","article-title":"Overexpression of chromodomain helicase DNA binding protein 5 (CHD5) inhibits cell proliferation and induces cell cycle arrest and apoptosis in chronic myeloid leukemia","volume":"10","author":"Xiong","year":"2021","journal-title":"Transl Cancer Res"},{"key":"B156","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.leukres.2016.05.007","article-title":"Cell adhesion induces overexpression of chromodomain helicase\/ATPase DNA binding protein 1-like gene (CHD1L) and contributes to cell adhesion-mediated drug resistance (CAM-DR) in multiple myeloma cells","volume":"47","author":"Xu","year":"2016","journal-title":"Leuk Res"},{"key":"B157","doi-asserted-by":"publisher","first-page":"15616","DOI":"10.1038\/ncomms15616","article-title":"INO80 exchanges H2A.Z for H2A by translocating on DNA proximal to histone dimers","volume":"8","author":"Brahma","year":"2017","journal-title":"Nat Commun"},{"key":"B158","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13072-019-0274-9","article-title":"The histone variant H2A.Z in gene regulation","volume":"12","author":"Giaimo","year":"2019","journal-title":"Epigenet Chromatin"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-01664-1","article-title":"H2A.Z overexpression suppresses senescence and chemosensitivity in pancreatic ductal adenocarcinoma","volume":"40","author":"\u00c1vila-L\u00f3pez","year":"2021","journal-title":"Oncogene"},{"key":"B160","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.molcel.2015.05.009","article-title":"Histone variant H2A","volume":"59","author":"Vardabasso","year":"2015","journal-title":"Z.2 Mediates Proliferation Drug Sensitivity Malignant Melanoma. Mol Cell"},{"key":"B161","doi-asserted-by":"crossref","DOI":"10.1007\/s10555-013-9486-9","article-title":"Histone H2A.Z deregulation in prostate cancer. Cause or effect","volume":"33","author":"Dryhurst","year":"2014","journal-title":"Cancer Metastasis Rev"},{"key":"B162","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41408-020-00389-w","article-title":"Genetic and epigenetic determinants of diffuse large B-cell lymphoma","volume":"10","author":"Bakhshi","year":"2020","journal-title":"Blood Cancer J"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2023.0234","article-title":"The interplay between H3K36 methylation and DNA methylation in cancer","volume":"20","author":"Dan","year":"2023","journal-title":"Cancer Biol Med"},{"key":"B164","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3727\/000000001783992731","article-title":"DNA methylation and histone deacetylation in the control of gene expression: basic biochemistry to human development and disease","volume":"9","author":"El-Osta","year":"2000","journal-title":"Gene Expr."},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00133-12","article-title":"KDM3B is the H3K9 demethylase involved in transcriptional activation of lmo2 in leukemia","volume":"32","author":"Kim","year":"2012","journal-title":"Mol Cell Biol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2017.07.009","article-title":"Epigenetics in myelodysplastic syndromes","volume":"51","author":"Heuser","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"B167","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41392-024-02039-0","article-title":"Epigenetics-targeted drugs: current paradigms and future challenges","volume":"9","author":"Dai","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0465","article-title":"Concise drug review: azacitidine and decitabine","volume":"18","author":"Derissen","year":"2013","journal-title":"Oncologist."},{"key":"B169","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1158\/1535-7163.MCT-08-0411","article-title":"Azacytidine causes complex DNA methylation responses in myeloid leukemia","volume":"7","author":"Stresemann","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01218-0","article-title":"Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies","volume":"35","author":"Stomper","year":"2021","journal-title":"Leukemia."},{"key":"B171","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs","volume":"3","author":"Kim","year":"2011","journal-title":"Am J Transl Res"},{"key":"B172","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-025-02285-w","article-title":"Preclinical and first-in-human of purinostat mesylate, a novel selective HDAC I\/IIb inhibitor, in relapsed\/refractory multiple myeloma and lymphoma","volume":"10","author":"Yang","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B173","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/B978-0-12-394387-3.00002-1","article-title":"Mechanisms of resistance to histone deacetylase inhibitors","volume":"116","author":"Lee","year":"2012","journal-title":"Adv Cancer Res"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02246-2","article-title":"Management of isocitrate dehydrogenase 1\/2 mutated acute myeloid leukemia","volume":"38","author":"Fruchtman","year":"2024","journal-title":"Leukemia."},{"key":"B175","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40364-019-0173-z","article-title":"Isocitrate dehydrogenase inhibitors in acute myeloid leukemia","volume":"7","author":"Liu","year":"2019","journal-title":"biomark Res"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-08915-1","article-title":"Perturbing LSD1 and WNT rewires transcription to synergistically induce AML differentiation","volume":"642","author":"Hosseini","year":"2025","journal-title":"Nature"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1744018\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T05:23:16Z","timestamp":1770268996000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1744018\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":176,"alternative-id":["10.3389\/fonc.2026.1744018"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1744018","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"article-number":"1744018"}}